Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Enalees inaugurates a new proteomics laboratory for the veterinary market


#Veterinary #diagnostic tests
Visite du nouveau laboratoire d'Enalees lors de son inauguration Visite du nouveau laboratoire d'Enalees lors de son inauguration

Enalees conceives, manufactures and markets next-generation (LAMP technology), rapid molecular diagnostic tests for the veterinary sector.
At Genopole since 2016, the company has just written another page in its history at the biocluster.
On Thursday, 6 April, Enalees’s president Laurent Thiery, and its CEO Eric Germain, inaugurated their new proteomics development and production laboratory in the presence of Bertrand Gaume, prefect of Essonne, Stéphane Beaudet, president of Genopole and vice-president of the Ile-de-France Region, Michel Bisson, president of the Grand Paris Sud Urban Area, Frédéric Prost, president of Medef Essonne, and Patrick Rakotoson, president of the CCI Essonne.

A part of Enalees’s development plan, the new laboratory received a €500,000 grant in 2022 from the Île-de-France Region within the framework of the France 2030 Investments for the Future (PIA) program. Therein were:

  • €300,000 to finance the acquisition of state of the art equipment
  • and €105,000, partially financed by SEM Genopole, for the completion of the new laboratory, located close to the company’s current premises.

Citation« Accompanying biocluster businesses at each phase of their development is one of Genopole’s pillars. We are delighted with this new accomplishment for Enalees and will continue to offer our help for the company’s future needs », declares David Bodet, deputy director of Genopole and GM of SEM Genopole.

To detect new pathogens…

To detect most notably twelve equine infectious diseases, including Lyme disease and equine influenza, the company deploys an isothermal amplification method. In France, 80% of equine veterinary clinics are equipped with it.
…the objective is to extend the range of tests.
The new laboratory will focus on producing new recombinant proteins specific to the detection of novel pathogenic agents present in infectious diseases and expanding the company’s reach beyond dogs, cats and horses.
Enalees plans to recruit a PhD and a qualified technician to accompany the lab’s launch.
With this new lab and in the medium term, Enalees may also be able to extend its service offer to third-party biotech and veterinary companies.

Citation« CThis new proteomics development and pilot production lab is evidence of the strategic industrial evolution that we’ve nurtured at Enalees and our strong capacity for innovation, a explains Laurent Thiery. JI thank all of the partners who made this inauguration possible, notably the Île-de-France Region, the Essonne Department and Genopole, who work every day to advance the region’s flourishing capacity for innovation».

Speaking of Enalees

CitationBertrand Gaume, prefect of Essonne: « Through a range of accompaniment measures (PIA, etc.) as well as its own investment program, France takes pride in accompanying this Essonne prodigy since its creation at Genopole. I admire the human and societal values forwarded by Enalees but also the industrial project it’s developing in Essonne. The inauguration of their new lab is a good illustration of the company’s increasingly determined march toward industrialization. »

CitationValérie Pécresse, Presidente of the Ile-de-France Administrative Region: « Representing 40% of French research and 31% of France’s GDP, the prolificacy of the Île-de-France ecosystem is exceptional. The Region happily plays its role in the development of its disruptive businesses, from the seed of an idea through to the marketing of the resulting innovation. The Region’s aid attributed to Enalees, at Genopole since 2016, illustrates well this continuum of accompaniment in a high-potential market and we are very happy to see the company’s growing success, which creates value and employment for the territory ».

CitationFrançois Durovray, President of the Essonne Departmental Council: « I am very proud to see this Essonnian biotech gem pursue its expansion with the inauguration Thursday 6 April of its new proteomics development and production laboratory at Genopole, France’s leading biocluster located in Évry-Courcouronnes. Enalees is a 100% Essonnian company proposing an innovative service for veterinary diagnostics unique in France. Its development is a veritable asset for our territory and the company’s partners in France and throughout the world. It shows the department’s momentum and confirms its growing renown as a future-focused place where tomorrow’s technologies take wing. At Genopole as on the Saclay plateau, innovation is a cornerstone for Essonne’s identity, its engaged actors and its promising ecosystem. Today still, one thing is certain: we hope to see Enalees continue its pursuit of success. »

Enalees and Genopole: hand-in-hand


Enalees set up shop at Genopole in 2016, only a few months after its creation.
David Bodet underlined the company’s commitment to life at Genopole.
Laurent Thiery played an active role in the Club of Genopole Entrepreneurs and acted as a mentor for young project holders in the Shaker program, who benefit from the advice of experienced entrepreneurs like him.
And reciprocally, Genopole is committed to Enalees. For example, in 2018, the company benefited from a Genopole grant funding a two-year postdoc internship to carry out a research project.

Article posted on 10 April 2023

Share
Highlights

Latest news


Journée Croda - table ronde intitulée « Essais cliniques phases 1 et 2 : comment surmonter les obstacles réglementaires et financiers ? » Nov. 2024

Genopole and Croda Pharma ally for the Biopharma Innovation Summit

Genopole partnered with Croda Pharma to organize the Biopharma Innovation Summit, a day-long scientific event dedicated to biopharmaceutical innovation.

Discover
Ibisc - Genopole's Laboratory

Optimizing the vital debriefing step in virtual reality training

The IBISC laboratory has developed an immersive debriefing module for virtual reality training and demonstrated its ability to optimize the vital debriefing step in that setting.

Discover
Genopole Partnering Week 2024 - un format hybride au service des biotechs

Partnering Week 2024: a hybrid edition for biotech innovation

Discover the highlights of Genopole Partnering Week 2024 (#GPW2024): a hybrid event bringing together start-ups, investors, and industry leaders to accelerate biotech innovation in health and the environment.

Discover
L'équipe de la Biofonderie de Paris dont Genopole est membre au GBA 2024 en Corée

Genopole’s actions for synthetic biology and the bioeconomy

Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.

Discover
Mission Bio Japan 2024 : Abolis Biotechnologies et Ispiron, accompagnées par Laurence Lacroix-Orio, directrice du Pôle Croissance et Prospection de Genopole, Paul Caroën, Program Manager et Alexis Biton, coordinateur des affaires internationales

Genopole’s mission to Japan – a country looking to lead in bioindustry

Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.

Discover
Les projets immobilier du biocluster Genopole - Evry

Real estate at Genopole: supporting growth through a strategic offer for workspace

With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.

Discover
Généthon - Vers une nouvelle génération de vecteurs viraux AAV pour la thérapie généique

The road toward a new generation of gene therapy vectors

Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.

Discover

Protopia: Genopole steps into a new era of prototyping

Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.

Discover
Equipe du laboratoire LBEPS

LBEPS : Athletic performance is also forged in the laboratory

Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.

Discover
Laboratoire de R&D - Abolis - campus Genopole

Abolis raises €35 million from an international consortium

Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.

Discover
Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Future FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
ACS Publication - Cover May 2024 - qui contient la publication du Lambe sur les nanopores

Lambe: A new milestone on the path to nanopore-based precision diagnostics

June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
Adnam Imeri et Jennifer Allouche, lauréats du programme financier ATIGE, créent leur équipe de recherche à Genopole respectivement en génomique et en biothérapies.

Two new research teams working on important subjects in genomics and innovative biotherapies

With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.

Discover
le programme national d’envergure PEPR Biothérapies et Bioproduction,  co-piloté par Cécile Martinat, est piloté par le CEA et l'Inserm

Four biocluster labs involved in the PEPR national program

Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
View all >
With the support from
Région île de France